Prognostic significance of therapy-induced senescence and SASP dynamics in acute myeloid leukemia: a retrospective cohort study
Cells damaged by leukemia treatment create a toxic environment that predicts poor survival, suggesting new drug targets to eliminate these lingering cells.
This retrospective study of 128 AML patients demonstrates that therapy-induced senescence creates a pro-tumorigenic microenvironment via SASP cytokines (IL-6, IL-8), and that high post-induction senescence burden independently predicts poor survival outcomes. The findings suggest senolytic strategies targeting residual senescent cells post-induction could represent a novel therapeutic avenue.
What the study was
- Study design
- Single-center retrospective cohort study
- Population
- Newly diagnosed AML patients treated with standard induction chemotherapy
- Sample size
- 128
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- BMC Cancer
Why it surfaced
Novel biomarker approach for AML prognosis using senescence markers with potential therapeutic implications (senolytics). Single-center retrospective limits generalizability but effect sizes are large and biologically plausible.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.